Clinical Trials
101 trialsAtezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
National Cancer Institute (NCI)
eVOLVE-Meso
AstraZeneca
PAPILLON
Janssen Research & Development, LLC
CHRYSALIS
Janssen Research & Development, LLC
B-FAST
Hoffmann-La Roche
NeoADAURA
AstraZeneca
MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
Mayo Clinic
NEOLA
AstraZeneca
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Boehringer Ingelheim
ARC-10
Arcus Biosciences, Inc.
VELOCITY-Lung
Gilead Sciences
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
National Cancer Institute (NCI)
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
MK-2870-009
Merck Sharp & Dohme LLC
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
Regeneron Pharmaceuticals
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
Eikon Therapeutics
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Amgen
REZILIENT4
Taiho Oncology, Inc.
TroFuse-020
Merck Sharp & Dohme LLC
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
TROPION-Lung12
AstraZeneca
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
MedImmune LLC
STAGGER
University of Utah
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
MK-7339-012
Merck Sharp & Dohme LLC
Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
Memorial Sloan Kettering Cancer Center
CheckMate-1533
Bristol-Myers Squibb
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer
Hoffmann-La Roche
MYSTIC
AstraZeneca
MAGELLAN
AstraZeneca
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Merck Sharp & Dohme LLC
Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors
Guangzhou Medical University
Chrysalis-2
Janssen Research & Development, LLC
MARIPOSA-2
Janssen Research & Development, LLC
A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
Hoffmann-La Roche
NIVIPI-Brain
Fundación GECP
NEPTUNE
AstraZeneca
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
Hoffmann-La Roche
IMbrella B
Hoffmann-La Roche
AVANZAR
AstraZeneca
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
National Cancer Institute (NCI)
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
BeOne Medicines
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Pfizer
HORIZON 2
Hoffmann-La Roche
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Hoffmann-La Roche